Members of the board and management exercise warrants and subscribe for shares in FluoGuide A/S
FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that board members and management have exercised all of their respective warrants of series TO1. In total this means that 112,322 warrants are to be converted, corresponding to a total investment of approximately DKK 668,000. In total, investments from the Board and Management correspond to approximately 10.5 percent of the total outstanding warrants of series TO1.
The FluoGuide warrants of series TO 1 that was issued in connection with FluoGuide’s issue of units, prior to listing on Spotlight Stock Market. The exercise period for the warrants TO 1 runs until and including 7 May 2020. Upon full exercise of all warrants of series TO 1, FluoGuide will be allocated approximately DKK 6.4 million (before costs). FluoGuide hereby announces that board members and management have chosen to exercise 112,322 warrants to subscribe for a total of 112,322 new shares in the Company. Below, each person’s amount of exercised warrants of series TO 1 is presented: Arne Ferstad (Member of the Board): 44,929 warrants; Grethe Nørskov Rasmussen (Chief Development Officer): 44,929 warrants; Peter Mørch Eriksen (Member of the Board): 18,720 warrants; and Micaela Sjökvist (Member of the Board): 3,744 warrants.
For further information regarding the warrants of series TO 1, please contact:
Sedermera Fondkommission
Phone: +46 40 - 615 14 10
E-mail: info@sedermera.se
www.sedermera.se
For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
__________________________________________________________________________________
About FluoGuide
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.
About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.
Tags: